Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development Will Be Presenting at the Accredited Members Spring Micro Cap Investor Conference in Las Vegas William R. Prather RPh, MD Will Present at the Conference on February 28, 2013 at 11:18 AM


Print article Print article
© Marketwire 2013
2013-02-25 17:53:30 -






HAIFA, ISRAEL--(Marketwire - February 25, 2013) - Pluristem Therapeutics, Inc. : www.pluristem.com/ (NASDAQ: PSTI) (TASE: PLTR), a leading developer of placenta-based cell therapies, announced today that William R. Prather RPh, MD, its Senior VP of Corporate Development, will be presenting the Company at the Accredited Members Spring Small Cap/Micro Cap Conference, being held at the JW Marriott Resort and Spa on February 27th, 28th
and March 1st. Dr. Prather will be presenting at 11:18 AM on February 28, 2013 in the Public Hall. Dr. Prather will also be available before and after his presentation to answer questions concerning Pluristem.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com : www.globenewswire.com/newsroom/ctr?d=262551&l=11&a=www.p .. , the content of which is not part of this press release.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.



at.marketwire.com/accesstracking/AccessTrackingLogServlet?prid=1 .. width="1" height="1" alt=" " border="0" />





Contact:


Pluristem Therapeutics Inc.:
William Prather R.Ph., M.D.
Sr. VP Corporate Development
1-303-883-4954

William.PratherMD@pluristem.com />
:
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580

daya@pluristem.com : docid: 20130225_11G003755-001.nitf -->



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com